Positions

Overview

  • Introduction:

    Dr. Pankit Vachhani is an Assistant Professor of Medicine at the University of Alabama at Birmingham and Associate Scientist of Experimental Therapeutics. He graduated from Weill Cornell Medical College in Qatar in 2012 and on to complete his internal medicine residency at Virginia Commonwealth University, followed by a fellowship in hematology/oncology at Roswell Park Comprehensive Cancer Center in Buffalo, NY.

    Clinical Interests & Research:

    At UAB, he is involved in multiple clinical trials as a principal investigator. He leads the Leukemia/BMT working group. His primary research interest is in hematological malignancies, particularly myeloproliferative neoplasms and AML, where he focuses on experimental therapeutics. He also serves as a panelist helping create the AML and MPN Treatment Guidelines for the National Comprehensive Cancer Network.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 How the COVID-19 Pandemic Reshaped the Management of Leukemia and Affected Patient Outcomes.  Current Treatment Options in Oncology.  23:688-702. 2022
    2022 Disease Modification in Myelofibrosis: An Elusive Goal?.  Journal of Clinical Oncology.  40:1147-1154. 2022
    2022 Impact of diagnostic genetics on remission MRD and transplantation outcomes in older AML patients..  Blood.  2022
    2022 Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy..  Journal of Clinical Oncology.  JCO2102188. 2022
    2022 Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval.  Leukemia Research.  112. 2022
    2021 Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.  Blood.  138:387-400. 2021
    2021 Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia..  Blood.  138:387-400. 2021
    2021 A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.  Leukemia Research.  107. 2021
    2021 Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis.  Journal for ImmunoTherapy of Cancer.  9. 2021
    2021 Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines 2021
    2021 Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia 2021
    2020 Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021 2020
    2020 Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series.  Hematology/Oncology and Stem Cell Therapy.  13:143-146. 2020
    2020 Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors 2020
    2020 Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.  Journal for ImmunoTherapy of Cancer.  8. 2020
    2020 Observation Versus Immediate Reinduction for Acute Myeloid Leukemia Patients With Indeterminate Day 14 Bone Marrow Results.  Clinical Lymphoma, Myeloma and Leukemia.  20:31-38. 2020
    2019 Acute promyelocytic leukemia during pregnancy: A case report and 10-year institutional review of hematologic malignancies during pregnancy 2019
    2019 Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission.  Blood.  134:48. 2019
    2019 Radiological imaging and bone marrow biopsy in staging of cutaneous B-cell lymphoma.  British Journal of Haematology.  184:674-676. 2019
    2019 Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature.  Case Reports in Oncology.  12:260-276. 2019
    2018 Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.  Leukemia Research.  75:29-35. 2018
    2018 All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisis.  Leukemia Research Reports.  10:16-19. 2018
    2017 Treatment of Relapsed/Refractory Acute Myeloid Leukemia.  Current Treatment Options in Oncology.  18. 2017
    2017 Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia.  Leukemia Research Reports.  7:36-39. 2017
    2017 Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib..  Case Reports in Hematology.  2017:9681832. 2017
    2016 VEGF inhibitors in renal cell carcinoma 2016
    2016 Spotlight on pembrolizumab in non-small cell lung cancer: The evidence to date.  OncoTargets and Therapy.  9:5855-5866. 2016
    2016 Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML..  Case Reports in Hematology.  2016:1259759. 2016
    2014 Remission of rheumatoid arthritis on brentuximab vedotin.  Rheumatology.  53:2314-2315. 2014
    2014 Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.  Physiological Genomics.  46:448-456. 2014
    2014 Isolated gastric myeloid sarcoma: a case report and review of the literature..  Case Reports in Hematology.  2014:541807. 2014
    2013 Maternal complications and neonatal outcome in Arab women of a fast developing country 2013
    2011 Obesity and low vision as a result of excessive Internet use and television viewing.  International Journal of Food Sciences and Nutrition.  62:60-62. 2011
    2010 Do excessive internet use, television viewing and poor lifestyle habits affect low vision in school children?.  Journal of Child Health Care.  14:375-385. 2010

    Chapter

    Year Title Altmetric
    2014 Can we cure CML without transplantation?.  279-326. 2014

    Research Overview

  • Dr Vachhani’s primary interest is in hematological malignancies, particularly acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). His specific research interests include developmental therapeutics and clinical trials for high-risk, elderly and relapsed AML.

    • Principal Investigator On

    Investigator On

  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP)  awarded by National Cancer Institute/NIH/DHHS
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by RHIZEN PHARMACEUTICALS SA
  • Private Grant  awarded by FORTY SEVEN, INC.
  • Private Grant  awarded by ASTEX PHARMACEUTICALS
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by ASTEX PHARMACEUTICALS
  • Private Grant  awarded by IMMUNOGEN, INC.
  • Private Grant  awarded by ONO PHARMACEUTICAL COMPANY LTD
  • Private Grant  awarded by KITE PHARMA
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by TG THERAPEUTICS
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by INNATE PHARMA
  • Private Grant  awarded by IMMUNOGEN, INC.
  • Private Grant  awarded by AFFIMED GMBH
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by TG THERAPEUTICS
  • Private Grant  awarded by SUTRO BIOPHARM
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by SELLAS LIFE SCIENCES GROUP, INC.
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by ASCENTAGE PHARMA GROUP INC
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by FATE THERAPEUTICS, INC.
  • Private Grant  awarded by DELTA-FLY PHARMA INC
  • Private Grant  awarded by KARTOS THERAPEUTICS INC.
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by MARKER THERAPEUTICS INC
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by EUSA PHARMA
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by SYROS PHARMACEUTICALS INC.
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University
  • UAB 1923: A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL) study  awarded by City of Hope
  • UAB 2078: A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non–Hodgkin Lymphoma of B-Cell Origin  awarded by ARTIVA BIOTHERAPEUTICS INC

    • Education And Training

  • Doctor of Medicine, 2012

    • Full Name

  • Pankit Vachhani